ADCs (Antibody-Drug Conjugates)
The Integrated Guard for ADC Excellence
Navigate the Biologics Frontier with Process Certainty
ADCs (Antibody-Drug Conjugates)
The ADC pipeline is exploding (100+ candidates globally), but success hinges on flawless execution across payload, linker, conjugation, and analytics. Fragmented vendors create blame-shifting "interface gaps," while DAR variability and linker instability derail programs. Aventiq Bio eliminates these risks with integrated oversight - leveraging India's emerging ADC powerhouse (single-use suites, advanced analytics) for faster, safer, and 40–60% more cost-effective development.
-
Interface Gap & Vendor Fragmentation
Payload, mAb, and conjugation often split across vendors - leading to blame-shifting when hand-offs fail.
-
DAR Variability & Linker Instability
Inconsistent drug loading or cleavage profiles compromising efficacy and safety.
-
Cold-Chain Fragmentation
Degradation risks during transit between specialized sites.
-
Analytical Blind Spots
Inadequate methods for DAR distribution, free drug, or conjugate impurities - failing EMA/FDA scrutiny
-
Waste Management Liability
Environmental and regulatory exposure from "active" conjugated Cytotoxic Payloads
India - The Emerging ADC Powerhouse
India is rapidly positioning itself as a next-generation ADC hub, with 15+ facilities offering payload synthesis, linker chemistry, conjugation, and fill-finish - many featuring cutting-edge single-use conjugation suites for speed and sustainability. The sector is growing at 30%+ CAGR, supported by OEB 5 containment and increasing USFDA/EMA inspections. "China+1" strategies make it ideal for oncology innovators. Aventiq Bio provides vetted access to this capacity with seamless interface management.
Integrated Oversight Across the ADC Lifecycle
We organize governance around the three critical pillars - ensuring seamless flow from potent Cytotoxic Payload to final conjugate.
Synthesis & Containment
- HPAPI Governance: Independent oversight of cytotoxic "warhead" synthesis in OEB 5/6 high-containment environments.
- Complex Synthetics: Technical mastery of Peptide linkers (Val-Cit-PABC) and next-gen Oligonucleotide payloads.
- Intermediate Purity: Oversight of ultra-pure Linker-Payload assemblies to meet stringent limits for unconjugated species"
The Conjugation Bridge
- Hand-off Logistics: Managing fragile cold-chain transitions between synthetic chemistry and bioprocessing sites.
- Aggregation Mitigation: On-ground monitoring of stoichiometry and pH to prevent protein sticking
- Fill-Finish Integrity: Validation of lyophilization cycles and light-protected primary packaging for long-term stability.
The Analytical Finality
- DAR Distribution: Independent verification of Drug-to-Antibody Ratio using HIC-HPLC and SEC-MALS for potency consistency.
- Impurity Profiling: Advanced characterization of unconjugated payloads and residual solvents (DMSO/DMF) post-purification.
- Cleavage Kinetics: Governance of stability studies to ensure precise payload release only within the target cellular environment.
Extended Conjugated Modalities
- Peptide–Drug Conjugates (PDCs):
Governance oversight across peptide linker–payload integration, stability, and controlled release—applying the same interface discipline used for ADC programs.
- Radiopharmaceutical Conjugates (RDCs):
Advisory governance for radionuclide conjugation, radiochemical purity, and decay-kinetics management—ensuring safety, regulatory alignment, and data integrity.
Why Aventiq Bio – Your Integrated ADC Guardian
Unique expertise at the HPAPI-biologics interface
Proprietary database of payload, conjugation, and fill-finish facilities
Proven hand-off protocols preventing costly delays
True independence - your single thread of truth
Track record accelerating oncology ADCs to clinic and approval